犬关节炎治疗市场- 依治疗类型（药物{NSAIDs}、补充剂{葡萄糖胺}、外科手术）、关节炎类型（骨关节炎、骨软骨病、类风湿性关节炎、创伤性关节炎）、全球预测（2024 - 2032）

犬关节炎治疗市场规模预计在2024年至2032年间复合年增长率将超过4.7%。这进一步推动了对有效治疗的需求，以减轻患病宠物的疼痛并改善其生活品质。根据关节炎基金会的数据，每五隻狗就有一隻患有犬类关节炎。宠物主人越来越意识到关节炎的症状和早期介入的重要性，导致对兽医咨询、诊断服务和治疗解决方案的强烈需求。

兽医领域不断发展的技术进步和创新也影响着市场的成长。新药的开发，包括非类固醇类抗发炎药物（NSAID）、缓解骨关节炎药物（DMOAD）和干细胞疗法等再生疗法，为兽医有效治疗犬类疾病提供了更广泛的选择关节炎。物理疗法、水疗法和关节保健补充剂等替代疗法的日益普及和普及将进一步扩大市场成长。

犬关节炎治疗行业分为治疗类型、关节炎类型和地区。

根据治疗类型，由于兽医外科技术的进步和外科干预措施的接受度不断提高，外科手术治疗类型细分市场的市场规模预计在 2024 年至 2032 年期间将出现显着的复合年增长率。关节镜检查、关节手术和矫正截骨术等手术变得越来越普遍，因为它们可以显着改善患有晚期关节炎的狗的活动能力和生活品质。这些手术得到更好的诊断工具和术后护理的支持，以提高其成功率和结果。

由于人们对犬类自体免疫关节炎疾病的日益认识以及针对这些疾病的标靶疗法的开发，预计到2032 年，类风湿性关节炎类型领域的犬关节炎治疗行业将录得可观的增长率。类风湿性关节炎虽然在狗身上比骨关节炎少见，但如果不及时治疗，可能会导致严重的疼痛和关节损伤。随着兽医学的发展，人们对狗自身免疫性关节炎的机制的了解不断加深，从而导致了新的治疗方案的开发，例如缓解疾病的药物和免疫抑制剂。

由于确保兽药安全性和有效性的严格监管标准以及不断增长的微创手术，欧洲犬关节炎治疗行业预计将在 2024 年至 2032 年期间持续成长。完善的兽医基础设施和高宠物拥有率正在增加对专业关节炎治疗的需求。对预防性治疗的高度重视以及欧洲宠物主人对关节炎治疗策略的认识不断增强也推动了该区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 提高人们对犬类健康的认识
    • 关节炎及相关疾病病例不断增加
    • 治疗技术的进步
  • 产业陷阱与挑战
    • 治疗费用高
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 药品
  • 非类固醇类抗发炎药 (NSAID)
  • 皮质类固醇
  • 阿片类止痛药
  • 其他药品
• 补充品
  • 葡萄糖胺
  • 软骨素
  • 甲磺酰甲烷
  • 其他补充剂
  • 药物和补充剂市场（按给药途径）
    • 口服
    • 可注射
    • 其他给药途径
  • 药品和补充剂市场（按配销通路）
    • 兽医院药房
    • 零售药局
    • 网路药局
• 外科手术
• 其他治疗类型

第 6 章：市场估计与预测：按关节炎类型，2021 - 2032

• 主要趋势
• 骨关节炎
• 骨软骨病
• 类风湿关节炎
• 创伤性关节炎

第 7 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 8 章：公司简介

• American Regent, Inc.
• Bayer AG
• Boehringer Ingelheim Animal Health
• CEVA Santé Animale
• Dechra Pharmaceuticals PLC
• Elanco Animal Health
• Nutramax Laboratories Veterinary Sciences, Inc.
• Vetoquinol SA
• VetStem, Inc.
• Virbac
• Zoetis Inc.

Canine Arthritis Treatment Market size is expected to register over 4.7% CAGR between 2024 and 2032. With the rising number of aging dogs, the incidence of arthritis, which is a common disease in older dogs, is increasing. This is further driving the demand for effective treatments to relieve pain and improve the quality of life of the sick pets. As per Arthritis Foundation, canine arthritis affects one out of every five dogs. Pet owners have grown increasingly aware of the symptoms of arthritis and the importance of early intervention, leading to the strong demand for veterinary consultations, diagnostic services, and treatment solutions.

Growing technological advancements and innovations in veterinary medicine are also influencing the market growth. The development of new drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying osteoarthritis drugs (DMOADs), and regenerative therapies, such as stem cell therapy, is offering veterinarians a wider range of options for effective treatment of canine arthritis. The increasing availability and popularity of alternative therapies like physical therapy, hydrotherapy and joint health supplements will further expand the market growth.

The canine arthritis treatment industry is classified into treatment type, arthritis type and region.

Based on treatment type, the market size from the surgical procedure treatment type segment is slated to witness significant CAGR during 2024-2032, owing to advancements in veterinary surgical techniques and the increasing acceptance of surgical interventions. Procedures, such as arthroscopy, joint surgery and corrective osteotomies are becoming more common as they significantly improve mobility and quality of life in dogs with advanced arthritis. These operations are supported by better diagnostic tools and post-operative care for improving their success and results.

Canine arthritis treatment industry from the rheumatoid arthritis type segment is predicted to record decent growth rate through 2032, driven by the increasing recognition of autoimmune arthritis conditions in dogs and the development of targeted therapies to address them. Rheumatoid arthritis, although less common in dogs than osteoarthritis, can cause severe pain and joint damages if left untreated. With developments in veterinary medicine, understanding of the mechanisms underlying autoimmune arthritis in dogs is increasing, leading to the development of new treatment options, such as disease-modifying drugs and immunosuppressants.

Europe canine arthritis treatment industry is poised to depict sustained growth during 2024-2032, attributed to stringent regulatory standards for ensuring the safety and efficacy of veterinary pharmaceuticals along with the growing minimally invasive surgeries. The well-established veterinary infrastructure and high pet ownership rate are increasing the demand for specialized arthritis treatment. The strong emphasis on preventive treatment and the growing awareness of European pet owners about arthritis treatment strategies are also fueling the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness regarding canine health
    • 3.2.1.2 Growing cases of arthritis and related disorders
    • 3.2.1.3 Advancement in technology for treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Non-steroidal anti-inflammatory drugs (NSAID's)
  • 5.2.2 Corticosteroids
  • 5.2.3 Opioid pain relievers
  • 5.2.4 Other drugs
• 5.3 Supplements
  • 5.3.1 Glucosamine
  • 5.3.2 Chondroitin
  • 5.3.3 Methylsulfonylmethane
  • 5.3.4 Other supplements
  • 5.3.5 Drugs and supplements market, by route of administration
    • 5.3.5.1 Oral
    • 5.3.5.2 Injectable
    • 5.3.5.3 Other routes of administration
  • 5.3.6 Drugs and supplements market, by distribution channel
    • 5.3.6.1 Veterinary hospital pharmacies
    • 5.3.6.2 Retail pharmacies
    • 5.3.6.3 Online pharmacies
• 5.4 Surgical procedures
• 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Arthritis Type, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Osteoarthritis
• 6.3 Osteochondrosis
• 6.4 Rheumatoid arthritis
• 6.5 Traumatic arthritis

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 American Regent, Inc.
• 8.2 Bayer AG
• 8.3 Boehringer Ingelheim Animal Health
• 8.4 CEVA Santé Animale
• 8.5 Dechra Pharmaceuticals PLC
• 8.6 Elanco Animal Health
• 8.7 Nutramax Laboratories Veterinary Sciences, Inc.
• 8.8 Vetoquinol SA
• 8.9 VetStem, Inc.
• 8.10 Virbac
• 8.11 Zoetis Inc.